 |
 |
ZADAXIN®: The Perfect Partner
in Hepatitis C Treatment
Hepatitis C virus (HCV) is the most common blood-borne RNA infection in
the world, with more than 170 million people infected. Of these, many
never receive treatment, and of those who do, more than 50% do not respond
at all or relapse after treatment. There is no vaccine available for this
virus, and the spread of HCV has been a growing threat for decades. An
active immune response is fundamental to the ultimate goal of viral clearance.
Now, ZADAXIN is energizing hepatitis C treatment worldwide. |
 |
Adding ZADAXIN to Interferon Treatment
| • |
Nearly doubles
HCV RNA viral clearance (1) |
| • |
Triples normalization
of ALT at end
of treatment (2) |
| • |
Increases histological
response rates
by 38% (1) |
| • |
Provides an improvement in
HAI Score:
2.44 vs 1.82 among monotherapy responders
(1) |
|
End-of-Treatment Response Viral RNA (1)
• PCR Response • 6 Month Rx •
75% Genotype (1) |
|
| • |
Produces
a higher sustained response
rate among previous nonresponders
(3) |
| • |
Results in a higher
sustained response
rate in patients with genotype 1 —
a poorly responsive population (4)
|
Back to top |
Sustained Virological Response Rates |
|
|
Even in the most difficult-to-treat patient groups, ZADAXIN stimulates
the immune system, enabling a higher rate of sustained responses.
ZADAXIN increases
the number of virus-fighting cells
– CD4 (T helper) cells
– CD8 (cytotoxic T) cells
– NK (natural killer) cells |
ZADAXIN helps
create a better targeting system
– Increases MHC Class 1
– Slows replication of virally infected cells
– Reduces oxidative stress |
| ZADAXIN’s dual mechanism
of action enables higher sustained virological response rates |
|
ZADAXINâs Unique
Dual Mechanism of Action
|
 |
|
|
Improving Quality of Life
Interferon therapy, while greatly beneficial to HCV patients, can cause
a number of potentially debilitating side effects. ZADAXIN has not been
shown to add to these side effects. You can feel comfortable adding ZADAXIN
to an IFN treatment regime. In fact, of more than 3,000 patients treated
in worldwide trials, less than 1% reported ZADAXIN-related adverse events.*
ZADAXIN: Virtually no evidence of adverse events.
Other HCV therapies: Adverse events associated with IFN or ribavirin
include neutropenia, hemolytic anemia, malaise/ fatigue, headache,
nausea, depression, abdominal discomfort, diarrhea, myalgia, and
insomnia. |
Comparative Adverse-Event Incidence |
|
|
Reaching the World
Approved in more than 25 countries.
*Adverse experiences have been infrequent and mild, consisting primarily
of local discomfort at the injection site,
and rare instances of erythema, transient muscle atrophy, polyarthralgia
combined with hand edema, and rash.
References: 1. Sherman KE, et al. Hepatology.
1998;27:1128-1135. 2. Sherman K, et al. In: Schinazi R, et al, eds. Therapies
for Viral Hepatitis C Virus and Related Viruses. Kyoto, Japan, 1997. 3.
Sherman K. Data on file. 4. Rasi G, et al. J Viral Hepat. 1996;3:191-196.
5. McHutchinson, et al. N Engl J Med. 1889;339:1485-1492. 6. Schlam, et
al. J Hepatol. 1999;31:184-188. 7. SciClone Pharmaceuticals Inc. Data
on file. 8. INTRON A [package insert]. Kenilworth, NJ: Schering Corporation;
2000. 9. REBETRON [package insert]. Kenilworth, NJ: Schering Corporation;
2000.
Back to top |
|
